A carregar...
Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis
BACKGROUND: The aim of the study was to evaluate the cost‐effectiveness of lenalidomide plus rituximab vs rituximab alone in patients with relapsed or refractory indolent lymphoma. METHODS: A Markov decision model was established to carry out the cost‐effectiveness analysis. Three discrete health st...
Na minha lista:
| Publicado no: | Cancer Med |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7402838/ https://ncbi.nlm.nih.gov/pubmed/32489014 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3121 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|